Vir Biotechnology Inc. Watch

from 10-Q 49 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Would Likely Cause Competitive Harm if Publicly Disclosed. Amended and Restated Collaboration and License Agreement by and Among Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc. Dated as of March 7, 2025

from 10-K 18 pages Vir Biotechnology, Inc. Change in Control and Severance Benefit Plan Approved by the Board of Directors: March 11, 2019, and Amended and Restated Effective as of January 1, 2025

from 10-K 14 pages Ex-10.13 Offer Letter (Mark Eisner)

from 10-K 1 page Ex-10.12 Promotion Letter (Vanina De Verneuil)

from 10-K 4 pages Vir Biotechnology, Inc. Discretionary Bonus Plan Article 1 Purpose of the Plan

from 10-K 3 pages Vir Biotechnology, Inc. Non-Employee Director Compensation Policy

from 10-Q 4 pages Other Transaction for Advanced Research (Otar) Agreement No.: 75a50122c00081 Between Vir Biotechnology, Inc. (“Recipient”) 1800 Owens Street, Suite 900 San Francisco, Ca 94158 And

from 10-Q 4 pages Other Transaction for Advanced Research (Otar) Agreement No.: 75a50122c00081 Between Vir Biotechnology, Inc 1800 Owens Street, Suite 900 San Francisco, Ca 94158 And

from 10-Q 17 pages Material contract

from 10-Q 70 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That Vir Biotechnology, Inc. Treats as Private or Confidential. License Agreement Between Amunix Pharmaceuticals, Inc. and Vir Biotechnology, Inc. Dated as of July 31, 2024

from 10-Q 5 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That Vir Biotechnology, Inc. Treats as Private or Confidential. February 21, 2024

from 10-Q 8 pages Other Transaction for Advanced Research (Otar) Agreement No.: 75a50122c00081 Between Vir Biotechnology, Inc 1800 Owens Street, Suite 900 San Francisco, Ca 94158 and the United States of America Department of Health and Human Services Biomedical Advanced Research and Development Authority 330 Independence Avenue, Sw G640 Washington, DC 20201 Concerning Pre-Exposure Prophylactic Monoclonal Antibodies for the Prevention of Influenza Illness and Medical Countermeasures for Other Emerging Pathogens of Pandemic Potential Agreement No.: 75a50122c00081 Amendment No. P00001

from 10-Q 39 pages Other Transaction for Advanced Research (Otar) Between Vir Biotechnology, Inc. 499 Illinois St, Suite 500 San Francisco, Ca 94158 and the United States of America Department of Health and Human Services Administration for Strategic Preparedness and Response Biomedical Advanced Research and Development Authority 330 Independence Avenue, Sw G640 Washington, DC 20201 Concerning Pre-Exposure Prophylactic Monoclonal Antibodies for the Prevention of Influenza Illness and Medical Countermeasures for Other Emerging Pathogens of Pandemic Potential

from 10-Q 8 pages Whereas A.HUMABS Biomed SA, Bellinzona and the Employee Entered Into an Employment Agreement With Effect as of March 2, 2022, Which Employment Agreement Has Been Amended and Assigned to the Company on December 19, 2022 (As Amended and Assigned, the Employment Agreement or Ea). B.ON September 19, 2023, the Company Gave Notice of Termination to the Employee Under the Employment Agreement. C.THE Company and the Employee Wish to Settle Amicably All Aspects of the Employment Relationship and the Termination Thereof, Subject to the Terms and Conditions Set Forth Herein. Now, Therefore, the Parties Hereto Enter Into the Following Agreement (The Agreement): 1. Termination of Employment and Payments to the Employee the Employee's Employment With the Company Shall Terminate by Mutual Consent With Effect as of March 31, 2024 (The Termination Date). for the Avoidance of Any Doubt, the Termination Date Shall Not Be Subject to Any Deferment for Whatever Reason. Until the Termination Date, the Company Shall Pay the Employee the Base Salary (Art. 6.2 Ea) of Chf 43,172.42 Per Month (Gross) as Well as the Benefits (Art. 7 Ea), Plus Reimburse the Expenses (Art. 8 Ea). on the Termination Date, the Company Shall Pay the Employee the Severance Pay (Art. 9 Ea) of Chf 129, 517 Gross. 2. Release From Obligation to Work and Commencement of New Employment

from 10-Q 10 pages Amendment No. 3 to Dca

from 10-Q 7 pages Amendment No. 2 to Dca

from 10-Q 18 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Would Likely Cause Competitive Harm if Publicly Disclosed. February 13, 2023 Sung Lee [***] [***]

from 10-Q 22 pages Via Electronic Mail January 19, 2023 Marianne De Backer Dear Marianne, on Behalf of Vir Biotechnology, Inc. (“Virbio” or the “Company”), I Am Pleased to Offer You Employment With the Company in the Position of Chief Executive Officer. This Letter Agreement (The “Agreement”) Sets Forth the Terms and Conditions of Your Employment With Virbio, Should You Accept Our Offer. 1

from 10-K 4 pages Agreement on Transfer of Employment and Amendment of Employment Agreement ("Agreement") Dated: December 19, 2022 Between Humabs Biomed SA (“Humabs”) via Dei Gaggini 3 6500 Bellinzona, Switzerland a Subsidiary of VIR Biotechnology, Inc. (“VIR”) 499 Illinois Street, Suite 500 San Francisco, Ca 94158 USA and Vir Biotechnology International Gmbh (“Vbi”) Grafenauweg 8 6300 Zug, Switzerland and Johanna Friedl-Naderer (“Employee”) [Address] [Address] (Humabs, Vbi and the Employee Together the "Parties", Each a "Party") (Humabs, Vbi and Their Direct and Indirect Affiliates (I.E. Any Entity Which, Directly or Indirectly, Controls, or Is Controlled By, or Is Under Common Control With Such Entity) From Time to Time the "Group", Each a "Group Company") Recitals Amendment of Section 3 Section 3 of the Employment Agreement Is Amended as Follows

from 10-K 4 pages Vir Biotechnology, Inc. Non-Employee Director Compensation Policy